AbbVie stock last traded at USD 266.40 on September 28, 2026
Published on 09/28/2026 at 22:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Trading session
AbbVie Inc. stock last traded at USD 266.40 on the New York Stock Exchange on September 28, 2026. The share was up 0.78 percent, or USD 2.06, from the previous session’s USD 264.34.
FDA approves Parkinson’s disease treatment
AbbVie announced on September 28 that the U.S. Food and Drug Administration approved JUVMO (tavapadon) tablets for the treatment of adults with Parkinson’s disease. The company said JUVMO is a once-daily treatment that may be used with or without levodopa therapy. The approval was supported by data from AbbVie’s Phase 3 TEMPO program. AbbVie said it expects JUVMO to become available to U.S. patients in October 2026.
AI drug-discovery collaboration
In a separate announcement dated September 21, AbbVie said it entered a multi-year collaboration with Iambic to accelerate the discovery and development of small-molecule therapies in immunology, neuroscience and oncology. Under the agreement, Iambic will receive an upfront payment and may receive success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The companies said the partnership will use Iambic’s AI platform alongside AbbVie’s therapeutic-area expertise.
